| Cancer immunoediting and resistance to T cell-based immunotherapy JS O’Donnell, MWL Teng, MJ Smyth Nature reviews Clinical oncology 16 (3), 151-167, 2019 | 1393 | 2019 |
| Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease J Liu, SJ Blake, MCR Yong, H Harjunpää, SF Ngiow, K Takeda, A Young, ... Cancer discovery 6 (12), 1382-1399, 2016 | 692 | 2016 |
| Resistance to PD1/PDL1 checkpoint inhibition JS O'Donnell, GV Long, RA Scolyer, MWL Teng, MJ Smyth Cancer treatment reviews 52, 71-81, 2017 | 517 | 2017 |
| PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux JS O’Donnell, D Massi, MWL Teng, M Mandala Seminars in cancer biology 48, 91-103, 2018 | 330 | 2018 |
| Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy N Glodde, T Bald, D van den Boorn-Konijnenberg, K Nakamura, ... Immunity 47 (4), 789-802. e9, 2017 | 237 | 2017 |
| The promise of neoadjuvant immunotherapy and surgery for cancer treatment JS O'Donnell, EP Hoefsmit, MJ Smyth, CU Blank, MWL Teng Clinical Cancer Research 25 (19), 5743-5751, 2019 | 156 | 2019 |
| Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies HY Chew, PO De Lima, JLG Cruz, B Banushi, G Echejoh, L Hu, ... Cell 180 (5), 895-914. e27, 2020 | 117 | 2020 |
| Tumor intrinsic and extrinsic immune functions of CD155 JS O’Donnell, J Madore, XY Li, MJ Smyth Seminars in cancer biology 65, 189-196, 2020 | 97 | 2020 |
| Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome J Liu, JS O’Donnell, J Yan, J Madore, S Allen, MJ Smyth, MWL Teng Oncoimmunology 8 (5), e1581530, 2019 | 88 | 2019 |
| RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer E Ahern, H Harjunpää, JS O'Donnell, S Allen, WC Dougall, MWL Teng, ... Oncoimmunology 7 (6), e1431088, 2018 | 88 | 2018 |
| Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma A Lepletier, J Madore, JS O'Donnell, RL Johnston, XY Li, E McDonald, ... Clinical Cancer Research 26 (14), 3671-3681, 2020 | 68 | 2020 |
| Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade? JS O’Donnell, MJ Smyth, MWL Teng Genome medicine 8, 1-3, 2016 | 64 | 2016 |
| Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy J Liu, EA Rozeman, JS O’Donnell, S Allen, L Fanchi, MJ Smyth, CU Blank, ... Oncoimmunology 8 (2), e1546068, 2019 | 52 | 2019 |
| Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016; 6: 1382–1399. doi: 10.1158/2159-8290 J Liu, SJ Blake, MC Yong, H Harjunpää, SF Ngiow, K Takeda, A Young, ... CD-16-0577.[Abstract][CrossRef][Google Scholar], 0 | 46 | |
| The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer E Pera, E Kaemmerer, MJG Milevskiy, KTDS Yapa, JS O’Donnell, ... Cancer cell international 16, 1-15, 2016 | 41 | 2016 |
| Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016; 6 (12): 1382–1399. doi: 10.1158/2159-8290 J Liu, SJ Blake, MCR Yong, H Harjunpää, SF Ngiow, K Takeda, A Young, ... doi. org/10.1158/2159-8290. cd-16-0577, 0 | 30 | |
| Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)? JS O’Donnell, KJ Chappell Frontiers in Microbiology 12, 724654, 2021 | 23 | 2021 |
| PD1 functions by inhibiting CD28-mediated co-stimulation JS O'donnell, MJ Smyth, MWL Teng Clinical & translational immunology 6 (5), e138, 2017 | 9 | 2017 |
| Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine JS O’Donnell, A Isaacs, V Jakob, C Lebas, JB Barnes, PC Reading, ... Frontiers in immunology 13, 976968, 2022 | 6 | 2022 |
| Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma JS O’Donnell, SK Hunt, KJ Chappell The Lancet Haematology 10 (7), e539-e548, 2023 | 3 | 2023 |
